- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02808104
Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
April 4, 2017 updated by: NLS Pharmaceutics
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether a controlled release formulation of mazindol is more effective than a placebo in the treatment of Attention Hyperactivity Disorder (ADHD) in adults.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This study is an outpatient, randomized, double-blind, placebo-controlled trial in which adult subjects with ADHD will be randomized to either oral mazindol controlled release or placebo once daily.
Subjects will be treated with study medication or placebo for 6 weeks with visits occurring weekly to measure efficacy and any adverse events with adjustment of medication dosing as necessary.
Study Type
Interventional
Enrollment (Actual)
84
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Newport Beach, California, United States, 92660
- AVIDA Clinic
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- CNS Healthcare
-
-
Massachusetts
-
Marshfield, Massachusetts, United States, 02050
- South Shore Psychiatric Services
-
-
Michigan
-
Rochester Hills, Michigan, United States, 48307
- Rochester Center for Behavorial Medicine
-
-
Missouri
-
St. Charles, Missouri, United States, 63304
- Midwest Research Group / St. Charles Psychiatric Associates
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Clinical Neuroscience Solutions
-
-
Texas
-
Houston, Texas, United States, 77007
- Memorial Park Psychiatry / Bayou City Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject has a primary diagnosis of ADHD established by a comprehensive psychiatric evaluation based on DSM-5 criteria.
- Subject is functioning at an appropriate level intellectually as judged by the investigator.
- Subject has a minimum baseline score of 28 at screen and at baseline using the ADHD-RS-DSM5
- Subject has a minimum score of 4 (moderate) on the CGI-S at screening.
- Women of child-bearing potential must be non-pregnant, non-lactating, and agree to be on an acceptable method of contraception. Acceptable methods of contraception include intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable), and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.
- In good general physical health as determined by medical history, a baseline physical examination, vital signs, clinical laboratory tests and electrocardiogram (ECG) measurement.
- Subject is fluent in written and spoken English and is willing and able to sign written informed consent prior to receipt of any study medication or beginning study procedures.
- Subject is willing and able to follow instructions, comply with the protocol requirements and make all required study visits.
Exclusion Criteria:
- Any primary DSM-5 Axis I disorder other than ADHD or any comorbid DSM-5 disorder that currently requires treatment.
- Lifetime history of any DSM-5 bipolar disorder
- Treatment with medications for any psychiatric or neurologic condition (e.g., amphetamines, MPH products, antidepressants, antipsychotics, mood stabilizers, anti-epileptics) or pressor agents concurrently or within 14 days of randomization.
- Concurrent medical illness that would interfere with the conduct of the study in the opinion of the investigator.
- History of significant cardiovascular disease, structural cardiac abnormality, cardiomyopathy, heart failure, serious heart rhythm abnormalities, coronary heart disease, transient ischemic attack or stroke, or other serious cardiac problems.
- Family history of sudden cardiac death.
- Clinically significant ECG abnormality or a QTc (Bazett correction) interval >450 msec.
- Resting sitting systolic blood pressure > 150 mm Hg or diastolic blood pressure > 90 mm Hg.
- BMI <18 or >40 kg/m2.
- Other medications that have CNS effects on cognition or attention (e.g., sedating antihistamines or decongestants).
- Positive drug screen (UDS) at screening (with the exception of current ADHD medication).
- Concomitant use of sensitive CYPA4/5 or CYP2D6 substrates with narrow therapeutic indices.
- Pregnant or lactating.
- Ongoing psychotherapeutic treatment for the treatment of ADHD begun less than three months before entry into this study.
- Recent or current DSM-5 Substance Use Disorder of moderate or greater severity (i.e., > 4 SUD symptoms), excluding nicotine.
- Suicidal ideation within past 3 months, suicidal behavior within the past year, or a C-SSRS score of 3, 4 or 5 on ideation item.
- Evidence of any out-of-range laboratory value at screening that has not been reviewed, approved and documented as not clinically significant by the Study Investigator.
- A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis), or any known/suspected hypersensitivity to any form of mazindol.
- Any other condition or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening that, in the opinion of the Study Investigator, would make the subject unsuitable for the study or put them at additional risk.
- Treatment with an investigational drug within 30 days preceding the first dose of study medication.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Matching placebo
|
|
Experimental: Mazindol Controlled Release
Mazindol controlled release taken once daily.
Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability.
Maximum dose during the study is 3 mg taken once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ADHD Rating Scale
Time Frame: weekly rating up to six weeks
|
weekly rating up to six weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Global Improvement Scale
Time Frame: weekly rating up to six weeks
|
weekly rating up to six weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2016
Primary Completion (Actual)
March 28, 2017
Study Completion (Actual)
March 28, 2017
Study Registration Dates
First Submitted
June 15, 2016
First Submitted That Met QC Criteria
June 16, 2016
First Posted (Estimate)
June 21, 2016
Study Record Updates
Last Update Posted (Actual)
April 6, 2017
Last Update Submitted That Met QC Criteria
April 4, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Adrenergic Uptake Inhibitors
- Mazindol
Other Study ID Numbers
- NLS-1001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Disorder With Hyperactivity
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Karolinska InstitutetCompletedAttention Deficit Disorder With Hyperactivity (ADHD)Sweden
-
Rabin Medical CenterNG Solutions LtdRecruitingADHD - Attention Deficit Disorder With HyperactivityIsrael
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
Clinical and Translational Genome Research Institute...Children's Specialized HospitalTerminatedAttention Deficit Disorders With HyperactivityUnited States
-
University of PennsylvaniaCompletedAttention Deficit Disorder With Hyperactivity (ADHD)United States
-
Massachusetts General HospitalRecruitingAttention Deficit Disorder With Hyperactivity | Attention Deficit DisorderUnited States
-
Nemours Children's ClinicCompletedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit DisorderUnited States
-
New River PharmaceuticalsShireCompletedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersUnited States
Clinical Trials on mazindol
-
NLS PharmaceuticsNot yet recruitingNarcolepsy Type 1 | Narcolepsy With Cataplexy
-
NLS PharmaceuticsCompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
NLS PharmaceuticsCompletedNarcolepsy | Excessive Daytime Sleepiness | Cataplexy NarcolepsyUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA); VA Connecticut Healthcare SystemCompleted